French medtech industry launches last-ditch effort to turn back most draconian reg changes
This article was originally published in Clinica
The French medtech industry is facing a change in its regulatory landscape as the new law on strengthening the healthcare system looms. But it has not given up the fight to resist some of the most far-reaching changes that threaten the ability of many of its members to survive.
You may also be interested in...
February sees some vitally important issues on the European Commission’s agenda, including areas where the medtech sector has been clamoring for progress in terms of clarity over the Commission's thinking and guidance documents. This year's meetings are plentiful and critical.
While the EU has selected the CND system as the basis for its nomenclature, GMDN is becoming increasingly valued on the US and international scene. How does it see its latest role panning out globally?
Updated medtech notified body figures from the European Commission always make headline news. But industry needs to see real appointments now, not a list of tricky-to-understand numbers.